Nura Adam Mohamed

Biography:

Dr. Nura Adam Mohamed, a graduate from the Biomedical Science Department, College of Health Sciences (CHS)-Qatar University. Who is now working as a Research Associate at the Biomedical Research Center (BRC) at Qatar University, has been awarded the L’Oréal-UNESCO for Women in Science Middle East Regional Young Talents ward 2021, which is a prestigious award designed to recognize young female scientists in the region.

Dr. Nura Mohamed, was one of nine winners in the Post-Doctorate Researchers category. She was recognized for her research towards developing nonconventional, novel therapeutic tools to prevent the development of diabetes mellitus and cardiovascular diseases. This regional initiative has recognized over 3,900 phenomenal researchers and 122 Laureates from more than 110 countries and regions since its inception 24 years ago.

Dr. Mohamed focuses on developing nano-formulations that have cardioprotective effects to battle the high prevalence of diabetes and its associated cardiovascular complications. Her research is gaining national and international attention, especially as the world moves towards targeted drug delivery, personalized medicine, and stem cell technologies, which can be achieved by using nanomaterials as drug carriers. Furthermore, she is focusing on the use of stem cell technologies in isolating progenitor cells from the patient’s blood which also aids in understanding the diseases’ progression, better establishing lab-oriented disease models in studying the different implications of the drug response on different people and help to bring these prototypes closer to the clinical trial phase.

This award will help Dr. Nura Mohamed pursue her research plan and establish collaborative ties with the leading experts in nanomedicine, cardiovascular diseases, and diabetes in Qatar, the UK, and Australia to further translate these prototypes to other disease areas. Dr. Mohamed believes that these prototypes hold great promise in the field of cardiovascular diseases and diabetes mellitus, which will provide a significant leap in developing better treatment options for diabetes mellitus and enhance the diabetes-nanomedicine field in Qatar, the GCC, and the world.